NCT00347971View on ClinicalTrials.gov

Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

recombinant human interleukin 21 and rituximab

rIL-21 (30, 100, 150 ug/kg) IV rituximab (375 mg/m2) IV

Trial Locations (1)

90095

University of California, Los Angeles, Los Angeles

Sponsors

Lead Sponsor

ZymoGenetics
All Listed Sponsors
lead

ZymoGenetics

INDUSTRY

NCT00347971 - Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter